Backed by extensive expertise in the healthcare and life sciences sectors, the fund manager has successfully executed over 30 transactions across Europe and North America. With a strategic focus on early to growth-stage investments, they emphasize a data-driven approach that leverages market trends and operational insights. Notable exits include several high-profile biotechnology firms, demonstrating a strong track record in maximizing value. Their operator-first strategy enhances portfolio companies' performance through active management and support.